RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwire - March 20, 2008) - Adherex Technologies Inc. (TSX: AHX)(AMEX: ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that Phase I and initial Phase II data from the Company’s Phase I/II study of systemic ADH-1 in combination with regional melphalan in melanoma has been accepted for presentation at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting, which takes place May 30 - June 3, 2008 in Chicago, IL.
